NCT06392009 - Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2026

Conditions

Tuberous Sclerosis ComplexFocal Cortical Dysplasia

Interventions

DRUG

Radiprodil

Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.

Trial Locations (20)

2650

RECRUITING

Universitair Ziekenhuis Antwerpen (UZA), Antwerp

3000

RECRUITING

University Hospitals Leuven, Pediatric Neurology, Leuven

3508

RECRUITING

UMC Uthrecht - Wilhelmina Kinderziekenhuis, Utrecht

4101

RECRUITING

Queensland Children Hospital, South Brisbane

16146

RECRUITING

IRCCS Istituto Giannina Gaslini, Genoa

28010

RECRUITING

Hospital Universitario Vithas La Milagrosa, Madrid

28034

RECRUITING

Hospital Ruber Internacional, Madrid

30363

RECRUITING

Centrum Medyczne Plejady, Krakow

50139

RECRUITING

AOU Meyer, Florence

60356

RECRUITING

Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan

80952

RECRUITING

Uniwersyteckie Centrum Kliniczne, Gdansk

T3A 2X6

RECRUITING

Alberta Children's Hospital, Calgary

M5G 1X8

RECRUITING

The Hospital for Sick Children (Sick Kids), Toronto

BC V6H 3N1

RECRUITING

BC Children's Hospital, Vancouver

00165

RECRUITING

Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Roma

00168

RECRUITING

"Universita Cattolica del Sacro Cuore - Policlinico Universitario Agostino Gemelli", Roma

04730

RECRUITING

Instytut Pomnik - Centrum Zdrowia Dziecka, Warsaw

08035

RECRUITING

Hospital Universitario Vall D´Hebrón, Barcelona

08950

RECRUITING

Hospital Materno Infantil Sant Joan de Deu de Barcelona, Barcelona

BS2 8BJ

RECRUITING

University Hospitals Bristol and Weston NHS Foundation Trust Bristol Royal Hospital for Children, Bristol